Provided by Tiger Fintech (Singapore) Pte. Ltd.

Denali Therapeutics Inc.

13.15
+0.41003.22%
Post-market: 13.400.2500+1.90%17:04 EDT
Volume:1.21M
Turnover:16.02M
Market Cap:1.91B
PE:-5.12
High:13.66
Open:12.59
Low:12.31
Close:12.74
Loading ...

Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer

TipRanks
·
04 Mar

Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025?

Insider Monkey
·
04 Mar

Denali Therapeutics : Oppenheimer Cuts Target Price to $42 From $50

THOMSON REUTERS
·
03 Mar

Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus

Zacks
·
01 Mar

Denali Therapeutics (DNLI) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
28 Feb

Denali: Entered Equity Distribution Agreement, Pursuant to Which Co May Offer, Sell Shares of Co Common Stock of up to $400 Mln From Time to Time

THOMSON REUTERS
·
28 Feb

BRIEF-Denali Therapeutics Files For Mixed Shelf Size Not Disclosed - SEC Filing

Reuters
·
28 Feb

Denali Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Denali Therapeutics Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
28 Feb

BRIEF-Denali Therapeutics Q4 Operating Income USD -129.846 Million

Reuters
·
28 Feb

Denali Therapeutics Inc - Expects 10%-15% Increase in Cash Operating Expenses for 2025

THOMSON REUTERS
·
28 Feb

Denali Therapeutics (DNLI) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
10 Feb

DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study

Zacks
·
07 Feb

Denali Therapeutics announces primary analysis of Phase 1/2 study in MPS II

TIPRANKS
·
07 Feb

BRIEF-Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa

Reuters
·
07 Feb

Denali Therapeutics Inc: Long-Term Safety Data Demonstrate That Tividenofusp Alfa Was Generally Well Tolerated

THOMSON REUTERS
·
07 Feb

Denali Therapeutics: Tividenofusp Alfa U.S. Launch Preparation Ongoing to Deliver Tividenofusp Alfa to Families With Mps Ii in Late 2025 or Early 2026

THOMSON REUTERS
·
07 Feb

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-up of Phase 1/2 Study in Hunter Syndrome (Mps Ii) With Tividenofusp Alfa

THOMSON REUTERS
·
07 Feb

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

GlobeNewswire
·
07 Feb

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (Mps Ii) and Transportvehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 Worldsymposium™

THOMSON REUTERS
·
30 Jan